CROMA-PHARMA
27.1.2022 15:28:08 CET | Business Wire | Press release
Croma-Pharma (Croma), today announced that the decentralized procedure for its botulinum toxin to gain market authorization in Europe has been accomplished. This important step is the basis to complete Croma’s already comprehensive portfolio.
Croma’s botulinum toxin submission in Europe is based on the data of 3 completed randomized, placebo-controlled phase III trials that enrolled a total of >1000 subjects in Europe and the US. National phases to grant the market authorization across Europe are following now.
A game changer for Croma-Pharma and the aesthetic industry
By adding its own botulinum toxin to the already broad portfolio Croma catapults itself to a new level within the aesthetic industry.
Offering already a wide selection of HA fillers, PDO threads, PRP and scientific skincare products, the botulinum toxin was the missing piece to compete with world leaders in this sector.
“We are pleased to announce that our toxin has now accomplished the decentralized procedure in Europe and will continue with the market authorization in major European countries in the next months. With this, we will now be able to complete our portfolio to meet all the needs of our customers”, Managing Director Andreas Prinz points out.
Partnership with Hugel
Croma has licensed the product from the Korean toxin producer Hugel Inc. for Europe and established a joint venture company in 2018 with Hugel, Inc., in order to develop and commercialize Croma’s HA filler products together with Hugel’s botulinum toxin product in the US, Canada, Australia and New Zealand.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.
About Hugel, Inc.
Established in Korea in 2001, Hugel is a global leader in medical aesthetics providing botulinum toxin formulation under different brand names such as BOTULAX and LETYBO in numerous countries across the world. Dedicated to provide proven, high quality medical aesthetic solutions that satisfy both consumers’ and practitioners’ needs, Hugel is leading the Korean market with its botulinum toxin.
PR2LET0122GMXb
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005535/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netmore and Cibicom Enter Strategic Partnership for Denmark and Introduce Unified Roaming Across the Nordics15.9.2026 08:00:00 CEST | Press release
Roaming with Digita provides seamless cross-border coverage while driving convergence toward a true global LoRaWAN® network Netmore Group, the leading network operator for Massive IoT, today announced that Cibicom has selected Netmore’s Operator Platform-as-a-Service (PaaS) to operate, optimize, and scale its nationwide LoRaWAN® network for Internet of Things (IoT) deployments. Cibicom is the largest LoRaWAN network operator in Denmark and provides critical communication infrastructure for nationwide broadcast and LTE450 services as well as tier 3 data center solutions and B2B fiber connectivity. The partnership means that Cibicom will replace its existing LoRaWAN Network Server with Netmore’s ThingPark Platform and that the Parties will work strategically together to ensure Danish customers can benefit from comprehensive and reliable LoRaWAN connectivity across Denmark. By leveraging Netmore's carrier-grade platform, Cibicom gains enhanced network scalability, seamless roaming, and hi
PSG Equity Holds Final Close of Third European Fund at Over €4.4 Billion15.9.2026 08:00:00 CEST | Press release
Fund hits hard cap; commitments significantly exceed size of PSG Europe IIStrong support from new and long-term investors signals continued demand for PSG Equity’s investment strategyFocused on scaling up European software and technology companies and building them into pan-European category leaders with global reach PSG Equity (“PSG”), a leading growth equity firm that specializes in partnering with software and technology-enabled services companies to drive transformational growth, today announced the final close of PSG Europe III (“PSGE III” or the “fund”) at over €4.4 billion in total committed capital. The fund reached its hard cap, receiving strong support from new and returning investors. PSGE III surpasses its €2.6 billion predecessor fund, which held its final close in October 2023. The Europe-focused fund saw commitments from state pension funds, sovereign wealth funds, insurance companies, family offices and high net worth individuals. PSGE III will continue the firm’s strat
Adabas & Natural Appoints Hans Roth as Chief Executive Officer15.9.2026 08:00:00 CEST | Press release
Experienced and accomplished enterprise technology executive to lead the next stage of AI-driven growth for the company’s mission-critical infrastructure software platform Adabas & Natural (A&N) today announced the appointment of Hans Roth as Chief Executive Officer, effective November 1. The appointment marks a defining moment as A&N enters its next chapter positioned for sustained, accelerating growth. Following the carveout of webMethods, StreamSets, Alfabet, Cumulocity, TrendMiner, and ARIS from Software GmbH, A&N is now back to its original roots as the multi-decade leading mission-critical database and infrastructure software suite. Roth joins from Red Hat, where he most recently served as Senior Vice President and General Manager for Europe, Middle East, and Africa (EMEA) and previously led Red Hat’s EMEA services business. Before joining Red Hat, Roth served as Vice President of the service delivery unit at Hewlett-Packard Enterprise for central Europe. “I’m thrilled to help bu
TreviPay Partners with Dynatos to Add e-Invoicing Capabilities to its B2B Payments Infrastructure15.9.2026 07:00:00 CEST | Press release
The partnership brings e-invoicing technology and compliance expertise into TreviPay’s B2B payments infrastructure as requirements expand across Europe and other markets TreviPay, a global B2B payments infrastructure partner, today announced a partnership with Dynatos to expand e-invoicing capabilities for TreviPay clients operating across Europe and other markets. Through the partnership, Dynatos Routty Cloud proposition will provide embedded e-invoicing technology and compliance support, helping TreviPay clients exchange invoices across different formats, networks and country requirements in Europe and other global markets. E-invoicing requirements continue to expand across Europe and other global markets, adding complexity for businesses managing invoices across more than 60 countries with mandates announced or already in place. At the same time, invoicing has become an increasingly important part of the B2B buyer experience. TreviPay research found 68% of B2B buyers are more likely
Meiji Group to Showcase Japanese-Quality CMO/CDMO Services and a Global Manufacturing Network at CPHI Milan 202615.9.2026 07:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (HQ: Chuo-ku, Tokyo; President and CEO: Toshiaki Nagasato) will debut as the Meiji Group’s Pharmaceutical Segment at CPHI Milan 2026, at Fiera Milano, Milan, Italy, October 6–8, 2026. At the exhibition, the Meiji Group’s Pharmaceuticals Segment will showcase 80 years of expertise in Japanese standard quality control, manufacturing, and supply network from Japan to Europe, India, and Southeast Asia. It will also highlight group-wide contract manufacturing, from development to supply, tailored to customer needs. Through the exhibition, Meiji Seika Pharma aims to raise global awareness of the Meiji Group’s Pharmaceutical Segment, its brands, capabilities, production capacity, and contract manufacturing services, and to forge new global partnerships to expand its CMO/CDMO business. “CPHI Milan 2026” Exhibition Overview Exhibition Name: CPHI Milan 2026 Dates: October 6 (Tue) – 8 (Thu), 2026 Venue: Fiera Milano (Milan, Italy) Exhibition Area: CMO Area Booth Numbe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom